Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Shunsuke Kiuchi , Shinji Hisatake , Yoshiki Murakami , et al Added: 1 year ago

Anticoagulation
The 7th Global NAFLD/MASLD Congress
Start date: Jun 24, 2024 End date: Jun 25, 2024
The conference is in production. If you would like to speak at this meeting contactlauren@globalengage.co.uk. NAFLD/MASLD continues to be a huge unmet clinical need globally, and although no therapy has received regulatory approval, there continues to be research advancing ourunderstanding of the disease’s mechanisms. Developments innon-invasivediagnostic biomarkerscontinue to offer the hope… View more

Cardiovascular Renal Metabolic
Thomas Treibel
Job title: Cardiology Registrar and NIHR Clinical Lecturer
Clinical academic cardiologist with specialist interest in valvular heart disease, heart failure and multimodality imaging. BHF Intermediate Clinical Research Fellow and Senior Lecturer in Cardiology at UCL; Honorary Consultant Cardiologist at Barts Health . Investigates myocardial fibrosis in aortic stenosis using cardiovascular magnetic resonance, cardiac CT and myocardial biopsies. Current… View more
Mark Linch
Job title: Associate Professor and Consultant in Uro-Oncology
Dr Mark Linch is an Associate Professor at University College London (UCL) Cancer Institute, where he leads the Urological Cancer Biology Group, and Honorary Consultant Medical Oncologist. Dr Linch trained in medical oncology at the Royal Marsden Hospital (RMH), London. In 2012 he was awarded a PhD in Cancer Cell Biology from UCL and the Cancer Research UK London Research Institute (LRI), now… View more
Ethical and Regulatory Frameworks Post-AI Act in Clinical Research
Author(s): Andrea Barucci , Valentina Colcelli , Salvatore De Masi , et al Added: 3 weeks ago

Digital Health

Guidelines & Statements
Semaglutide Modulates Key Pathways to Resolve MASH, Proteomic Analysis Reveals
Added: 6 months ago Source:  Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that… View more

Cardiovascular Renal Metabolic
Clinical Management of Non-alcoholic Steatohepatitis
Author(s): Carlos Millán-Rodríguez , Carlos Palacios Castelló , María de Regla Caballero-Valderrama , et al Added: 2 years ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 3 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 3 months ago

Demographic

Heart Failure